The coexistence of the BCR::ABL1 rearrangement and CALR mutation may change the clinical and laboratory manifestations of MPN and, for instance, in CML patients may be misinterpreted as failure of TKI therapy or disease transformation. Here, CALR is linked to myeloproliferative neoplasm.